THERAPEUTIC DRUG MONITORING FOR ANTI-TUMOR NECROSIS FACTOR AGENTS IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

被引：0
|
作者：
El-Dallal, Mohammed
Elfituri, Amin
Ghori, Sahin
Hoffman, Gila
Shah, Raj
Mishkin, Brooke
Feuerstein, Joseph D.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1529
引用
收藏
页码：S805 / S805
页数：1
相关论文
共 50 条
  • [1] Is Therapeutic Drug Monitoring for Anti-tumour Necrosis Factor Agents in Adults With Inflammatory Bowel Disease Ready for Standard of Care? A Systematic Review and Meta-analysis
    Shah, Raj
    Hoffman, Gila R.
    El-Dallal, Mohammed
    Goldowsky, Alexander M.
    Chen, Ye
    Feuerstein, Joseph D.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (08): : 1057 - 1065
  • [2] Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases
    Yarur, Andres J.
    Rubin, David T.
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (07) : 1709 - 1718
  • [3] Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 854 - 855
  • [4] The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease
    Joosse, Maria E.
    Samsom, Janneke N.
    van der Woude, C. Janneke
    Escher, Johanna C.
    van Gelder, Teun
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (09) : 2214 - 2221
  • [5] Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease Reply
    Bouguen, Guillaume
    Brunet, Tanguy
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 855 - 856
  • [6] Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    GASTROENTEROLOGY, 2019, 157 (04) : 922 - 924
  • [7] Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
    Yunho, Jung
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2020, 75 (01): : 1 - 3
  • [8] Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis
    Zheng, Fang-Yuan
    Yang, Kai-Si
    Min, Wen-Cheng
    Li, Xin-Zhu
    Xing, Yu
    Wang, Shuai
    Zhang, Ying-Shi
    Zhao, Qing-Chun
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 16 (02):
  • [9] THE EFFICACY OF THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Dias, Shiluka
    Sethi, Sonika
    Kumar, Aditi
    Brookes, Matthew
    Segal, Jonathan
    GUT, 2022, 71 : A46 - A46
  • [10] Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease? A Systematic Review and Meta-Analysis
    Barnes, Edward L.
    Allegretti, Jessica R.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2016, 50 (09) : 733 - 741
12345